Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Leukocyte Telomere Attrition following Radiotherapy in Prostate Cancer: A Prospective Study

January 23, 2026

[Scientific Reports] Researchers analyzed the influence of radiotherapy on leucocyte telomere length in prostate cancer patients. A total of 314 patients treated with curative radiotherapy for prostate cancer were included in the present prospective study.

Circulating Tumor Cells As a Window into Lethality in Prostate Cancer

January 23, 2026

[Nature Reviews Urology] Understanding the clinical utility of circulating tumour cells (CTCs) and future innovations is crucial to incorporating CTCs into the clinical management of prostate cancer.

Recent Advances and Future Prospects of Immunotherapeutic Approaches in Prostate Cancer

January 23, 2026

[Journal of Translational Medicine] The authors provide a comprehensive summary of current advances and persisting challenges in the field of prostate cancer immunotherapy.

Novel Therapy Using Engineered Immune Cells to Kill Prostate Cancer Earns $1.8 Million Department of Defense Grant

January 23, 2026

[VCU Massey Comprehensive Cancer Center] Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine were awarded a $1.8 million, 3-year grant from the United States Department of Defense to study the implications of using a modified enhanced therapeutic version of melanoma differentiation associated gene-7/IL-24 ‘Superkine’ delivered by immune cells to fight advanced prostate cancer.

RIPK2 Induces Docetaxel Resistance in Prostate Cancer through the NF-κB/P-Gp Signaling Pathway

January 23, 2026

[PloS One] Researchers elucidated the role and mechanism of action of receptor-interacting protein kinase 2 (RIPK2) in prostate cancer cell resistance to docetaxel.

Neuregulin Induces Prostate Cancer Cell Migration via HER3/HER2-FAK/Src Signaling Axis

January 23, 2026

[Cancer Cell International] The authors investigated the effects of neuregulin-1 β (NRG1) on prostate cancer cell behavior and elucidated the underlying molecular mechanisms.

A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader Molecules

January 20, 2026

[Cancer Research] To explore the utility of SWI/SNF therapy beyond androgen receptor (AR)-sensitive CRPC, scientists investigated SWI/SNF-targeting agents in AR-negative CRPC.

Reversing Enhancer RNA-Mediated IKBKE Gene Repression Enables Synthetic Anticancer Immunity in Prostate Cancer Models

January 20, 2026

[Journal of Clinical Investigation] Researchers demonstrate that androgen receptor pathway inhibitor plus irradiation triggered robust anticancer immunity in prostate cancers in both patients and mice.

Lactate Derived from Cancer-Associated Fibroblasts Promotes Alternative Splicing and Castration Resistance in Prostate Cancer

January 20, 2026

[Science Advances] The authors identified APCDD1+ cancer-associated fibroblasts as a distinct stromal population that secretes lactate into the tumor microenvironment in response to androgen deprivation therapy.

Regulation of Androgen Receptor Expression by Enhancer Elements in Prostate Cancer

January 20, 2026

[Experimental & Molecular Medicine] Elucidating the role of enhancer elements in driving androgen receptor (AR) overexpression and aberrant AR signaling may uncover new therapeutic targets for CRPC.

Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, a First-of-Its-Kind Treatment for Localized Prostate Cancer

January 9, 2026

[Alessa Therapeutics] Alessa Therapeutics announced that the US FDA has granted Fast Track designation for Enolen®, the Company’s lead product candidate for the treatment of low to intermediate risk, localized prostate cancer.

Butterfly Medical Announces Completion of Pivotal Trial for Minimally Invasive Treatment of Benign Prostatic Hyperplasia

January 9, 2026

[Butterfly Medical (BioSpace)] Butterfly Medical, developer of a non-surgical solution for benign prostatic hyperplasia (BPH), announced the successful completion of the final 12-month follow-up for all patients in its international pivotal clinical study. The landmark study was designed to evaluate the safety and efficacy of the Butterfly Prostatic Retraction Device, a first-line interventional therapy for BPH.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.